Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q2

4483.TEDINET S100PLQM
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥12.1bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.3bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥21.8bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.6bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥5.0bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥2.2bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥1.7bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥909m2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥2.2bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.1bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.7bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥908m2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥678m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.1bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥597m2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥677m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥1.1bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥598m2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥112.1bnat 2022-09-30Cons.Assets IFRS
Total assets¥62.1bnat 2022-03-31Cons.Assets IFRS
Total assets¥58.1bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥50.5bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥30.9bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥61.6bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥28.9bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥28.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥61.6bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.2bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥28.9bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥41.5bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥15.5bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.9bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥3.8bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥21.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥8.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥3.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥48.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥2.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥25.292022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.762022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥57.742021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥20.262021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥10.642021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥23.862022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.142022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥54.162021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.062021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥102021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio55.0%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio49.8%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 72
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥189m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥99m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-07-01 → 2022-09-30¥933m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-07-01 → 2022-09-30¥890m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥84m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-09-30¥192m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-07-01 → 2022-09-30¥144m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-07-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥24m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-07-01 → 2022-09-30¥903m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥924m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-07-01 → 2022-09-30¥485m
—segment totalrevenue2022-04-01 → 2022-09-30¥12.2bn
—segment totalrevenue2022-07-01 → 2022-09-30¥6.4bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥6.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥126m
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥67m
—segment totalsegment profit2022-04-01 → 2022-09-30¥3.1bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥1.5bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥88m
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-09-30−¥53m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥88m
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-09-30−¥53m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥157m
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-09-30−¥82m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2021-04-01 → 2021-09-30¥1.7bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2021-07-01 → 2021-09-30¥877m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.6bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2021-07-01 → 2021-09-30¥847m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥56m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥29m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2021-04-01 → 2021-09-30¥163m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2021-07-01 → 2021-09-30¥113m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2021-04-01 → 2021-09-30¥5.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2021-07-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2021-04-01 → 2021-09-30¥5.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2021-07-01 → 2021-09-30¥3.0bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥31m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥23m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2021-04-01 → 2021-09-30¥1.7bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2021-07-01 → 2021-09-30¥877m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2021-04-01 → 2021-09-30¥2.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2021-07-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2021-04-01 → 2021-09-30¥2.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2021-07-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2021-04-01 → 2021-09-30¥730m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2021-07-01 → 2021-09-30¥400m
—segment totalrevenue2021-04-01 → 2021-09-30¥9.6bn
—segment totalrevenue2021-07-01 → 2021-09-30¥5.1bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥9.6bn
—segment totalrevenue external2021-07-01 → 2021-09-30¥5.0bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥88m
—segment totalrevenue intersegment2021-07-01 → 2021-09-30¥53m
—segment totalsegment profit2021-04-01 → 2021-09-30¥2.6bn
—segment totalsegment profit2021-07-01 → 2021-09-30¥1.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 883
ItemContextValueUnit
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember13000000JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember140000000JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember140000000JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember-1000000JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember0JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember-0JPY
Issuance of new shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember14732000000JPY
Issuance of new shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember14558000000JPY
Issuance of new shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Issuance of new shares ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Issuance of new shares ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Issuance of new shares ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember-0JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Increase decrease by business combination ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Increase decrease by business combination ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Increase decrease by business combination ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Increase decrease by business combination ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Increase decrease by business combination ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Increase decrease by business combination ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Transfer to retained earnings ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Transfer to retained earnings ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Transfer to retained earnings ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Transfer to retained earnings ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Transfer to retained earnings ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-6000000JPY
Transfer to retained earnings ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Total transactions with owners IFRSCurrentYTDDuration_ShareCapitalIFRSMember14872000000JPY
Total transactions with owners IFRSCurrentYTDDuration_CapitalSurplusIFRSMember14698000000JPY
Total transactions with owners IFRSCurrentYTDDuration_TreasurySharesIFRSMember-0JPY
Total transactions with owners IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Total transactions with owners IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-6000000JPY
Total transactions with owners IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember11000000JPY
Equity IFRSCurrentQuarterInstant_ShareCapitalIFRSMember23964000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass